Market Overview

ICON Awarded Clinical Research Team of the Year and Best in Health Economics and Outcomes Research


ICON Wins Multiple Awards at the 2019 Clinical and Research
Excellence Awards

ICON plc, (NASDAQ:ICLR) a global provider of drug and device
development and commercialisation services to pharmaceutical,
biotechnology, medical device industries, today announced that it has
been awarded the Clinical Research Team of the Year (with Eli Lilly and
Company), for the second consecutive year, and Best in Health Economics
and Outcomes Research (with Bristol-Myers Squibb and LATITUDE, powered
by AXON). The awards were presented at the annual Clinical and Research
Excellence (CARE) Awards, which took place in Boston, Mass. on 2 May

The awards indicated are ICON's third win for Clinical Research Team of
the Year since the inaugural CARE Awards in 2016, and first win in the
Best Health Economics and Outcomes Research category. These awards
honoured the achievements of the teams and are a testament to the
company's overall strength of partnership in the industry.

ICON and Eli Lilly and Company won the award for the successful
execution of a full-service Cardiovascular Outcomes Trial (CVOT), in
which they were able to achieve exceptional patient retention despite
early challenges. The team's proactive management and flawless
execution, resulted in the data disclosure of the first Type 2 Diabetes
Mellitus medicine to demonstrate superiority in the reduction of major
adverse cardiac events (MACE) in a clinical trial that included a
majority of participants who did not have established cardiovascular
(CV) disease.

The ICON team, together with Bristol-Meyers Squibb and LATITUDE (powered
by AXON), were able to execute a long-term oncological trial comparing
treatment regimens with three different therapeutics, over five years,
in multiple geographies. ICON demonstrated significant expertise through
the application of a Real World Evidence approach, which met the needs
of the sponsor, the clinician, the patient and the payer.

Commenting on the award, ICON's Chief Executive Officer, Steve Cutler,
said: "We are delighted that our comprehensive approach to partnership
as well as the expertise of our clinical research teams has received
industry recognition. One of our key priorities is helping our clients
expedite drug development to improve outcomes and this has been
successfully achieved through the diligence and work ethic of the joint
partnership teams."

About ICON plc
ICON plc is a global provider of drug and
device development and commercialisation services to pharmaceutical,
biotechnology, medical device and government and public health
organisations. The company specialises in the strategic development,
management and analysis of programs that support clinical development -
from compound selection to Phase I-IV clinical studies. With
headquarters in Dublin, Ireland, ICON employed approximately 13,920
employees in 90 locations in 37 countries as at March 31, 2019.

Further information is available at


This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial